Works by Lewis, Katherine E.

Results: 21
    1
    2

    Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

    Published in:
    PEDS: Protein Engineering, Design & Selection, 2010, v. 23, n. 3, p. 115, doi. 10.1093/protein/gzp073
    By:
    • Mabry, Robert;
    • Lewis, Katherine E.;
    • Moore, Margaret;
    • McKernan, Patricia A.;
    • Bukowski, Thomas R.;
    • Bontadelli, Kristen;
    • Brender, Ty;
    • Okada, Shannon;
    • Lum, Karen;
    • West, James;
    • Kuijper, Joseph L.;
    • Ardourel, Dan;
    • Franke, Secil;
    • Lockwood, Luann;
    • Vu, Tuyen;
    • Frank, Amanda;
    • Appleby, Mark W.;
    • Wolf, Anitra;
    • Reardon, Brian;
    • Hamacher, Nels B.
    Publication type:
    Article
    3
    4
    5

    Beyond Error Patterns.

    Published in:
    Learning Disability Quarterly, 2016, v. 39, n. 4, p. 199, doi. 10.1177/0731948716658063
    By:
    • Lewis, Katherine E.
    Publication type:
    Article
    6
    7
    8

    ICOSL<sup>+</sup> plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist.

    Published in:
    Science Translational Medicine, 2020, v. 12, n. 564, p. 1, doi. 10.1126/scitranslmed.aay4799
    By:
    • Adom, Djamilatou;
    • Dillon, Stacey R.;
    • Yang, Jinfeng;
    • Liu, Hao;
    • Ramadan, Abdulraouf;
    • Kushekhar, Kushi;
    • Hund, Samantha;
    • Albright, Amanda;
    • Kirksey, Maykala;
    • Adeniyan, Titilayo;
    • Lewis, Katherine E.;
    • Evans, Lawrence;
    • Wu, Rebecca;
    • Levin, Steven D.;
    • Mudri, Sherri;
    • Yang, Jing;
    • Rickel, Erika;
    • Seaberg, Michelle;
    • Henderson, Katherine;
    • Gudgeon, Chelsea J.
    Publication type:
    Article
    9
    10
    11

    Dyscalculia in Algebra: A Case Study.

    Published in:
    Insights into Learning Disabilities, 2022, v. 19, n. 1, p. 3
    By:
    • Lewis, Katherine E.;
    • Sweeney, Gwendolyn;
    • Thompson, Grace M.;
    • Adler, Rebecca M.;
    • Alhamad, Kawla
    Publication type:
    Article
    12
    13
    14
    15

    Becoming a Researcher: A Reflection.

    Published in:
    Journal of Education, 2016, v. 196, n. 2, p. 63, doi. 10.1177/002205741619600204
    By:
    • SCHOENFELD, ALAN H.;
    • LEWIS, KATHERINE E.
    Publication type:
    Article
    16
    17

    The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29286-5
    By:
    • Maurer, Mark F.;
    • Lewis, Katherine E.;
    • Kuijper, Joseph L.;
    • Ardourel, Dan;
    • Gudgeon, Chelsea J.;
    • Chandrasekaran, Siddarth;
    • Mudri, Sherri L.;
    • Kleist, Kayla N.;
    • Navas, Chris;
    • Wolfson, Martin F.;
    • Rixon, Mark W.;
    • Swanson, Ryan;
    • Dillon, Stacey R.;
    • Levin, Steven D.;
    • Kimbung, Yengo Raymond;
    • Akutsu, Masato;
    • Logan, Derek T.;
    • Walse, Björn;
    • Swiderek, Kristine M.;
    • Peng, Stanford L.
    Publication type:
    Article
    18
    19

    Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101).

    Published in:
    Arthritis & Rheumatology, 2023, v. 75, n. 8, p. 1344, doi. 10.1002/art.42484
    By:
    • Dillon, Stacey R.;
    • Evans, Lawrence S.;
    • Lewis, Katherine E.;
    • Debrot, Susan;
    • Blair, Tiffany C.;
    • Mudri, Sherri;
    • Kleist, Kayla;
    • Levin, Steven D.;
    • Bhandari, Janhavi G.;
    • Garrett, Logan;
    • Wolfson, Martin F.;
    • Holland, Pamela M.;
    • Rixon, Mark W.;
    • Peng, Stanford L.
    Publication type:
    Article
    20

    Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases.

    Published in:
    Arthritis & Rheumatology, 2023, v. 75, n. 7, p. 1187, doi. 10.1002/art.42462
    By:
    • Evans, Lawrence S.;
    • Lewis, Katherine E.;
    • DeMonte, Daniel;
    • Bhandari, Janhavi G.;
    • Garrett, Logan B.;
    • Kuijper, Joseph L.;
    • Ardourel, Daniel;
    • Wolfson, Martin F.;
    • Debrot, Susan;
    • Mudri, Sherri;
    • Kleist, Kayla;
    • Griffin, Luana L.;
    • Hebb, LuAnne;
    • Sanderson, Russell J.;
    • Wang, NingXin;
    • Seaberg, Michelle;
    • Chunyk, Allison G.;
    • Yang, Jing;
    • Hong, Youji;
    • Maria, Zahra
    Publication type:
    Article
    21

    The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29286-5
    By:
    • Maurer, Mark F.;
    • Lewis, Katherine E.;
    • Kuijper, Joseph L.;
    • Ardourel, Dan;
    • Gudgeon, Chelsea J.;
    • Chandrasekaran, Siddarth;
    • Mudri, Sherri L.;
    • Kleist, Kayla N.;
    • Navas, Chris;
    • Wolfson, Martin F.;
    • Rixon, Mark W.;
    • Swanson, Ryan;
    • Dillon, Stacey R.;
    • Levin, Steven D.;
    • Kimbung, Yengo Raymond;
    • Akutsu, Masato;
    • Logan, Derek T.;
    • Walse, Björn;
    • Swiderek, Kristine M.;
    • Peng, Stanford L.
    Publication type:
    Article